REDUCTOR


Protocolnummer:
EudraCT 2013-002616-28

Ziekenhuizen:
NKI / A.v.L ziekenhuis Amsterdam

Titel:
Cytoreductive treatment of dabrafenib combined with trametinib to allow complete surgical resection in patient with BRAF mutated, prior unresectable stage lll or lV melanoma.

Behandeling:
dabrafenib combined with trametinib

Stadium:
Stadium irresectable IIIc/IV

Belangrijkste in/exclusiecriteria:
In: Patient with unresectable stage lll melanoma or stage lV with < or = 3 resectable metastases, confirmed BRAF mutation-positive melanoma, evaluable disease by CT/MRI or PET, patient are able to swallow an retain oral medication. Ex: ocular or primary mucosal melanoma, any investigational anti-cancer or other drug within 28 days or 5 half-lives, a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency, active gastrointestinal disease.

Contactpersoon:
Prof. J. Haanen

Alle trials